Innovative Treatments for
Cytokine Release Syndrome
Novel therapies address the life-threatening symptoms associated with CRS
Our ScienceCytoAgents Overview
CytoAgents is focused on the development of innovative pharmaceutical products for the treatment of symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, commonly known as cytokine storm.
Our Team- PHASE I TRIALS COMPLETE
- PHASE II TRIALS TARGETED Q2 2022
- MULTIPLE THERAPEUTIC AREAS
- PROVEN SAFETY PROFILE
Therapeutic Areas
CytoAgents is focused on addressing Cytokine Release Syndrome across a number of therapeutic areas of high unmet need
Therapy
Dermatitis
Brain Injury
Covid-19
Our Science
MODULATING CYTOKINE AMPLIFICATION
CytoAgents’ lead compound, CTO1681, targets the underlying cause of life-threatening CRS and is positioned to be a new, breakthrough therapy. Our successful completion of Phase 1 trials showed that CTO1681 is proven to be safe.
Our SciencePartners & Investors
CytoAgents has made tremendous progress in the fight against Cytokine Release Syndrome. We have successfully completed Phase I Human Clinical Trials and are currently planning Phase II trials.
Join us as we transform CRS through a novel approach that allows for prevention as well as treatment.
Executive Summary